Comingling RNA barcodes, each correlating to a neuron, indicate where neurons connect in the brain, letting researchers map neural connection with speed, scale and resolution.
Illustration Credit: Michael Vincent.
Scientific Frontline: Extended "At a Glance" Summary: Connectome-seq
The Core Concept: Connectome-seq is a high-throughput brain-mapping platform that employs unique RNA "barcodes" to tag individual neurons, facilitating the simultaneous mapping of thousands of neural connections at single-synapse resolution.
Key Distinction/Mechanism: Traditional brain mapping relies on labor-intensive tissue slicing and microscopic imaging, while older sequencing-based techniques only trace a neuron's general trajectory without identifying its specific synaptic partners. In contrast, Connectome-seq translates spatial connectivity into a sequencing problem. It uses specialized proteins to transport and anchor unique RNA barcodes directly at the synapse. By isolating these synaptic junctions and utilizing high-throughput sequencing, researchers can read which barcode pairs colocalize, precisely revealing which neurons are connected.
Major Frameworks/Components:
- RNA Barcoding: The assignment of unique molecular identifiers to distinctly tag individual neuron cells within a network.
- Synaptic Anchoring: The deployment of specialized transport proteins to carry RNA barcodes from the neuron's cell body and secure them at the synaptic junctions.
- High-Throughput Sequencing: The computational and molecular process of isolating synaptic junctions and sequencing the localized RNA to read out connected barcode pairs at scale.
- Pontocerebellar Circuit Mapping: The initial validation of the platform, which successfully mapped over 1,000 neurons in a specific mouse brain circuit and uncovered previously unknown connectivity patterns between cell types.
Branch of Science: Neuroscience, Molecular Biology, Cell and Developmental Biology.
Future Application: Researchers aim to scale this technology to map the entire mammalian brain comprehensively. The platform also serves as a foundational tool for developing circuit-guided therapeutic interventions tailored to specific neural pathways.
Why It Matters: Connectome-seq drastically reduces the time and cost associated with mapping elaborate neural pathways, allowing for scalable comparisons between healthy brains and those at different stages of disease. This high-resolution mapping could pinpoint the exact origins of circuit dysfunction in neurodegenerative conditions, such as Alzheimer's disease, and psychiatric disorders—potentially identifying vulnerabilities before clinical symptoms even appear.
By tagging neurons with molecular “barcodes,” researchers mapped connections among thousands of neurons in the mouse brain with unprecedented speed and resolution.
The approach could expand understanding not only of the layout of elaborate networks in the brain, but also how the brain functions, what happens when there is dysfunction and how neurodegenerative diseases progress.
“When engineering a computer, you need to know the circuitry of the central processing unit. If you don’t know how everything is wired together, you can’t understand its function, optimize it or fix it when something breaks. We are approaching the brain the same way,” said study leader Boxuan Zhao, a professor of cell and developmental biology at the University of Illinois Urbana-Champaign.
“Our technology enables simultaneous mapping of thousands of neural connections with single-synapse resolution — a capability that doesn’t exist in any current technology. It is directly applicable to understanding circuit dysfunction in neurodegenerative diseases and could provide a platform for developing circuit-guided therapeutic interventions,” he said.
Traditionally, brain mapping has been a long, laborious process involving cutting the brain into very thin slices, imaging with different types of microscopes and trying to reconstruct neural pathways. Newer sequencing-based techniques can label thousands of neurons at once, but most trace only where a neuron reaches to — not which specific partner it connects with at the synapse, Zhao said.
Zhao’s group developed a platform, Connectome-seq, that uses RNA “barcodes” to tag each neuron. Specialized proteins carry the RNA barcodes from the neuron’s cell body and anchor them at the synapse, the junction between two neurons. The researchers then isolate the synaptic junctions and use high-throughput sequencing to read out which pairs of RNA barcodes ended up together, revealing which neurons are connected at large scale.
“We translated the neural connectivity problem into a sequencing problem. Imagine a big bunch of balloons. The main body of each balloon has its unique barcode stickers all over it, and some move down to the end of the string. If two balloons are tied together at the end, the two barcodes meet at the junction,” Zhao said. “Then we snip out the knots and sequence the barcodes in each one. If the same knot has stickers from balloon A and balloon B, we know these two balloons are tied together. We are doing this in the brain, just on the level of thousands of neuron cells. With this information, we can reconstruct a sophisticated map that represents the connections among all these seemingly floaty groups.”
The researchers used Connectome-seq to map more than 1,000 neurons in a mouse brain circuit called the pontocerebellar circuit, which connects two different regions of the brain. They revealed previously unknown connectivity patterns, including connections between cell types that were not previously known to be directly wired together in the adult brain.
“With improvements already underway in our lab, we are confident that we can make it even better and eventually reach the goal of mapping the whole mouse brain,” Zhao said.
Due to its speed and ability to map large areas, Connectome-seq has potential to accelerate research into neurodegenerative conditions, psychiatric disorders and other neurological conditions, Zhao said, by enabling comparison between connections in healthy brains and brains at different stages of disease.
“With sequencing-based approaches, the time and cost are greatly reduced, which really makes it possible to see differences in different brains. We could see where connections change, where the most vulnerable parts of the brain are, perhaps before symptoms even appear,” Zhao said. “For example, if we can catch where exactly the weak link is that kick starts the whole catastrophic cascade in Alzheimer’s disease, can we specifically strengthen those connections to where the disease slows or does not progress?”
Funding: A Neuro-omics Initiative grant from Wu Tsai Neurosciences Institute of Stanford University supported this work, along with grants from the Elsa U. Pardee Foundation and the Edward Mallinckrodt Jr. Foundation.
Published in journal: Nature Methods
Authors: Danping Chen, Alina Isakova, Zhou Wan, Mark J. Wagner, Yunming Wu, and Boxuan Simen Zhao
Source/Credit: University of Illinois Urbana-Champaign | Liz Ahlberg Touchstone
Reference Number: ns031426_02
.jpg)